Dapoo Biotech, incubated at the Hong Kong University of Science and Technology, was founded in 2018 and is committed to providing world-leading life science tools. It stands as a leading enterprise in China's high-throughput droplet microfluidic technology sector. The company has established R&D and production centers in Shenzhen and Jiaxing, with a team of nearly 100 R&D professionals. Focused on applying droplet microfluidic technology to the fields of biomedicine and precision medicine, Dapoo Biotech strives to become a comprehensive solution provider integrating the R&D and production of microfluidic chips, instruments, and reagents.

     Multiple scientific instruments based on droplet microfluidic technology have been commercialized, including the CytoSpark Droplet Microfluidic High-throughput Screening System, the OMNIdrop System, the Galaxy Single Cell Analysis System, the Nebula dPCR System, and the Exostar Extracellular Vesicles Analysis System. These instruments can be applied in various fields such as antibody screening, directed evolution of enzymes, strain screening, small molecule compound screening, cancer research, early tumor screening, virus quantification, and biological product quality inspection.

     Currently, we have served over 100 renowned top biopharmaceutical and in vitro diagnostic companies, university research institutes, and State Key Laboratories, achieving multiple firsts in the domestic and international biopharmaceutical field and gaining widespread recognition in the industry.

     Corporate website: https://www.dp-bio.com/